By Lee Greenberger, PhD, Chief Scientific Officer at LLS | April 5, 2022 The U.S. Food and Drug Administration (FDA) last week approved axicabtagene ciloleucel (axi-cel, Yescarta®) for patients with large B-cell lymphoma (LBCL) who either did not respond to first-line standard chemotherapy or relapsed within 12 months. Until now, CAR T-therapies like axi-cel have been saved for blood cancer patients who have…